UBS AM
JNCE

UBS AM’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

UBS AM’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-114,972
Closed -$1.79M – 2611
2017
Q3 		$1.79M Hold
114,972
– – ﹤0.01% 1451
2017
Q2 		$1.61M Sell
114,972
-10,588
-8% -$227K ﹤0.01% 1440
2017
Q1 		$2.76M Buy
+125,560
New +$2.66M ﹤0.01% 1214

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

UBS AM's JNCE Position: Q4 2017 in Review

UBS AM sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2017, closing a stake of 114,972 shares — an estimated $1.79M sold.

UBS AM first reported a position in JNCE in Q1 2017 and held it in 3 quarters. The position peaked at $2.76M in Q1 2017. 83 funds tracked by Wall St. Rank hold JNCE as of Q4 2017.

  • UBS AM reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • UBS AM sold 114,972 Jounce Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $1.79M.
  • UBS AM first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • UBS AM's Jounce Therapeutics, Inc. Common Stock position peaked at $2.76M in Q1 2017.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2017.

Based on UBS AM's 13F filing for Q4 2017, filed 9 Feb 2018.